These data partially contribute to the interpretation of the clinical data, even if they are not fully consistent with the finding by Sarkar et al. These authors demonstrated that rhPRG4 is able to offset TGFβ-induced enhancement of migration and invasion of breast cancer cell line MDA-MB231, but this capacity requires rhPRG4 to interact with CD44 to interfere with its pro-invasive downstream signaling. This evidence concerns the gene TGFB1 and breast carcinoma.